Roos, I., Hughes, S., McDonnell, G., Malpas, C. B., Sharmin, S., Boz, C., Alroughani, R., Ozakbas, S., Buzzard, K., Skibina, O., van der Walt, A., Butzkueven, H., Scott, J. G., Kuhle, J., Terzi, M., Laureys, G., Van Hijfte, L., John, N., Grammond, P. ... MSBase Study GroupDanish MS Registry Study Group (2023).
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
JAMA Neurology,
80(8), 789-797.
https://doi.org/10.1001/jamaneurol.2023.1625
Govande, A. A., Babnis, A. W., Urban, C., Habjan, M.
, Hartmann, R., Kranzusch, P. J. & Pichlmair, A. (2023).
RNase L-activating 2'-5' oligoadenylates bind ABCF1, ABCF3 and Decr-1.
The Journal of general virology,
104(9), Article 104:001890.
https://doi.org/10.1099/jgv.0.001890
Bril, V., Drużdż, A., Grosskreutz, J., Habib, A. A., Mantegazza, R., Sacconi, S., Utsugisawa, K., Vissing, J., Vu, T., Boehnlein, M., Greve, B., Woltering, F., Bozorg, A., Gayfieva, M., Kaminski, H. J. & MG0003 study team (2023).
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
The Lancet Neurology,
22(5), 383-394.
https://doi.org/10.1016/S1474-4422(23)00077-7
Iversen, L., Conrad, C., Eidsmo, L., Costanzo, A., Narbutt, J., Pinter, A., Kingo, K., Rivera Diaz, R., Kolbinger, F., Nanna, M., Frueh, J. A. & Jagiello, P. (2023).
Secukinumab demonstrates superiority over narrow-band ultraviolet B phototherapy in new-onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study.
Journal of the European Academy of Dermatology and Venereology : JEADV,
37(5), 1004-1016.
https://doi.org/10.1111/jdv.18846